Krystal Biotech Inc. (KRYS)
KRYS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1711279/000171127926000016/0001711279-26-000016-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | KRYS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2017 |
| SEC CIK | 0001711279 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DELAWARE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $389.1M |
| Net income | $204.8M |
| Operating income | $161.3M |
| Net margin | 52.6% |
| Operating margin | 41.5% |
| Revenue growth | +33.9% |
| Cash | $496.3M |
| Total assets | $1.3B |
| P/E (computed) | 43.1× |
| P/S (computed) | 22.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-02 |
| Cash and burn | $462.8M cash; operating cash flow $81.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 29,633,472 (2026-10-28); 28,997,519 a year earlier; 28,206,330 three years earlier. | Cover page 2026-10-28 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Pittsburgh, Pennsylvania, United States | PCAOB Form AP 2026-03-11 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $95.2M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $127.3M | $63.1M | $91.2M | $462.8M | No debt tags | $470.0M | 10-Q 2026-11-02 |
| Q2 2026 2026-06-30 | $119.2M | $54.8M | $74.8M | $427.7M | No debt tags | $440.5M | 10-Q 2026-08-03 |
| Q1 2026 2026-03-31 | $116.4M | $55.9M | $80.4M | $501.3M | No debt tags | $417.3M | 10-Q 2026-05-04 |
| Q4 2025 2025-12-31 | $107.1M | $51.4M | $77.5M | $496.3M | No debt tags | $389.1M | 10-K 2026-02-17 |
| Q3 2025 2025-09-30 | $97.8M | $79.4M | $39.7M | $392.6M | No debt tags | $373.2M | 10-Q 2026-11-02 |
| Q2 2025 2025-06-30 | $96.0M | $38.3M | $52.7M | $353.8M | No debt tags | $359.2M | 10-Q 2026-08-03 |
| Q1 2025 2025-03-31 | $88.2M | $35.7M | $31.0M | $308.8M | No debt tags | $333.4M | 10-Q 2026-05-04 |
| Q4 2024 2024-12-31 | $91.1M | $45.5M | $52.8M | $344.9M | No debt tags | $290.5M | 10-K 2026-02-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2023-07-18 |
| Latest annual report | 10-K | 2026-02-17 |
| Latest quarterly / interim | 10-Q | 2026-11-02 |
| Latest current report | 8-K | 2026-11-02 |
| Latest proxy | DEFA14A | 2026-04-03 |
Source: SEC EDGAR submissions feed, 514 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.4% |
| 1 month | -5.0% |
| 3 months | -7.0% |
| Year to date | +23.8% |
| 1 year | +51.7% |
| From 52-week high | -19.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PCVX | Vaxcyte Inc. | $61.61 | -2.78% | $9.8B |
| QGEN | Qiagen N.V. Common Shares | $49.81 | -0.16% | $10.3B |
| CGON | CG Oncology Inc. | $84.78 | +13.95% | $7.6B |
| RGEN | Repligen Corporation | $162.78 | -2.99% | $10.4B |
| KYMR | Kymera Therapeutics Inc. | $125.85 | -1.35% | $10.7B |
| HALO | Halozyme Therapeutics Inc. | $96.50 | -3.76% | $11.0B |
| TWST | Twist Bioscience Corporation | $105.04 | -5.88% | $7.0B |
| IMVT | Immunovant Inc. | $33.28 | -2.63% | $6.9B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier